Antiviral efficacies of currently available rescue therapies for multidrug-resistant chronic hepatitis B.

Mi Sung Park, Beom Kyung Kim, Kyung Sik Kim, Ja Kyung Kim, Seungup Kim, Junyong Park, doyoung kim, Oidov Baartarkhuu, KwangHyub Han, Chae Yoon Chon, SangHoon Ahn

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The incidence of multidrug-resistant (MDR) chronic hepatitis B (CHB) during sequential lamivudine (LAM) and adefovir dipivoxil (ADV) treatment is increasing. We investigated the antiviral efficacies of various rescue regimens in patients who failed sequential LAM-ADV treatment. Forty-eight patients (83.3% of whom were HBeAg-positive) who failed sequential LAM-ADV treatment were treated with one of the following regimens: entecavir (ETV) (1 mg) monotherapy (n=16), LAM+ADV combination therapy (n=20), or ETV (1 mg)+ADV combination therapy (n=12). All patients had confirmed genotypic resistance to both LAM and ADV and were evaluated every 12 weeks. The baseline characteristics and treatment duration did not differ significantly among the study groups. During the treatment period (median duration: 100 weeks), the decline of serum HBV DNA from baseline tended to be greatest in the ETV+ADV group at all-time points (week 48: -2.55 log(10) IU/mL, week 96: -4.27 log(10) IU/mL), but the difference was not statistically significant. The ETV+ADV group also tended to have higher virologic response rates at 96 weeks compared to the ETV monotherapy or LAM+ADV groups (40.0% vs. 20.0% or 20.0%, P=0.656), and less virologic breakthrough was observed compared to the ETV monotherapy or LAM+ADV groups (8.3% vs. 37.5% or 30.0%; P=0.219), but again, the differences were not statistically significant. HBeAg loss occurred in one patient in the ETV+ADV group, in two in the ETV monotherapy group, and in none of the LAM+ADV group. The safety profiles were similar in each arm. There was a nonsignificant tendency toward better antiviral efficacy with ETV+ADV combination therapy compared to LAM+ADV combination therapy and ETV monotherapy for MDR CHB in Korea, where tenofovir is not yet available.

Original languageEnglish
Pages (from-to)29-35
Number of pages7
JournalUnknown Journal
Volume19
Issue number1
DOIs
Publication statusPublished - 2013 Jan 1

Fingerprint

Chronic Hepatitis B
Antiviral Agents
Lamivudine
Therapeutics
Hepatitis B e Antigens
Tenofovir
adefovir dipivoxil
entecavir
Korea

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Molecular Biology

Cite this

Park, Mi Sung ; Kim, Beom Kyung ; Kim, Kyung Sik ; Kim, Ja Kyung ; Kim, Seungup ; Park, Junyong ; kim, doyoung ; Baartarkhuu, Oidov ; Han, KwangHyub ; Chon, Chae Yoon ; Ahn, SangHoon. / Antiviral efficacies of currently available rescue therapies for multidrug-resistant chronic hepatitis B. In: Unknown Journal. 2013 ; Vol. 19, No. 1. pp. 29-35.
@article{599a50803c524114a167efe53c24622f,
title = "Antiviral efficacies of currently available rescue therapies for multidrug-resistant chronic hepatitis B.",
abstract = "The incidence of multidrug-resistant (MDR) chronic hepatitis B (CHB) during sequential lamivudine (LAM) and adefovir dipivoxil (ADV) treatment is increasing. We investigated the antiviral efficacies of various rescue regimens in patients who failed sequential LAM-ADV treatment. Forty-eight patients (83.3{\%} of whom were HBeAg-positive) who failed sequential LAM-ADV treatment were treated with one of the following regimens: entecavir (ETV) (1 mg) monotherapy (n=16), LAM+ADV combination therapy (n=20), or ETV (1 mg)+ADV combination therapy (n=12). All patients had confirmed genotypic resistance to both LAM and ADV and were evaluated every 12 weeks. The baseline characteristics and treatment duration did not differ significantly among the study groups. During the treatment period (median duration: 100 weeks), the decline of serum HBV DNA from baseline tended to be greatest in the ETV+ADV group at all-time points (week 48: -2.55 log(10) IU/mL, week 96: -4.27 log(10) IU/mL), but the difference was not statistically significant. The ETV+ADV group also tended to have higher virologic response rates at 96 weeks compared to the ETV monotherapy or LAM+ADV groups (40.0{\%} vs. 20.0{\%} or 20.0{\%}, P=0.656), and less virologic breakthrough was observed compared to the ETV monotherapy or LAM+ADV groups (8.3{\%} vs. 37.5{\%} or 30.0{\%}; P=0.219), but again, the differences were not statistically significant. HBeAg loss occurred in one patient in the ETV+ADV group, in two in the ETV monotherapy group, and in none of the LAM+ADV group. The safety profiles were similar in each arm. There was a nonsignificant tendency toward better antiviral efficacy with ETV+ADV combination therapy compared to LAM+ADV combination therapy and ETV monotherapy for MDR CHB in Korea, where tenofovir is not yet available.",
author = "Park, {Mi Sung} and Kim, {Beom Kyung} and Kim, {Kyung Sik} and Kim, {Ja Kyung} and Seungup Kim and Junyong Park and doyoung kim and Oidov Baartarkhuu and KwangHyub Han and Chon, {Chae Yoon} and SangHoon Ahn",
year = "2013",
month = "1",
day = "1",
doi = "10.3350/cmh.2013.19.1.29",
language = "English",
volume = "19",
pages = "29--35",
journal = "Review of Economic Dynamics",
issn = "1094-2025",
publisher = "Academic Press Inc.",
number = "1",

}

Antiviral efficacies of currently available rescue therapies for multidrug-resistant chronic hepatitis B. / Park, Mi Sung; Kim, Beom Kyung; Kim, Kyung Sik; Kim, Ja Kyung; Kim, Seungup; Park, Junyong; kim, doyoung; Baartarkhuu, Oidov; Han, KwangHyub; Chon, Chae Yoon; Ahn, SangHoon.

In: Unknown Journal, Vol. 19, No. 1, 01.01.2013, p. 29-35.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Antiviral efficacies of currently available rescue therapies for multidrug-resistant chronic hepatitis B.

AU - Park, Mi Sung

AU - Kim, Beom Kyung

AU - Kim, Kyung Sik

AU - Kim, Ja Kyung

AU - Kim, Seungup

AU - Park, Junyong

AU - kim, doyoung

AU - Baartarkhuu, Oidov

AU - Han, KwangHyub

AU - Chon, Chae Yoon

AU - Ahn, SangHoon

PY - 2013/1/1

Y1 - 2013/1/1

N2 - The incidence of multidrug-resistant (MDR) chronic hepatitis B (CHB) during sequential lamivudine (LAM) and adefovir dipivoxil (ADV) treatment is increasing. We investigated the antiviral efficacies of various rescue regimens in patients who failed sequential LAM-ADV treatment. Forty-eight patients (83.3% of whom were HBeAg-positive) who failed sequential LAM-ADV treatment were treated with one of the following regimens: entecavir (ETV) (1 mg) monotherapy (n=16), LAM+ADV combination therapy (n=20), or ETV (1 mg)+ADV combination therapy (n=12). All patients had confirmed genotypic resistance to both LAM and ADV and were evaluated every 12 weeks. The baseline characteristics and treatment duration did not differ significantly among the study groups. During the treatment period (median duration: 100 weeks), the decline of serum HBV DNA from baseline tended to be greatest in the ETV+ADV group at all-time points (week 48: -2.55 log(10) IU/mL, week 96: -4.27 log(10) IU/mL), but the difference was not statistically significant. The ETV+ADV group also tended to have higher virologic response rates at 96 weeks compared to the ETV monotherapy or LAM+ADV groups (40.0% vs. 20.0% or 20.0%, P=0.656), and less virologic breakthrough was observed compared to the ETV monotherapy or LAM+ADV groups (8.3% vs. 37.5% or 30.0%; P=0.219), but again, the differences were not statistically significant. HBeAg loss occurred in one patient in the ETV+ADV group, in two in the ETV monotherapy group, and in none of the LAM+ADV group. The safety profiles were similar in each arm. There was a nonsignificant tendency toward better antiviral efficacy with ETV+ADV combination therapy compared to LAM+ADV combination therapy and ETV monotherapy for MDR CHB in Korea, where tenofovir is not yet available.

AB - The incidence of multidrug-resistant (MDR) chronic hepatitis B (CHB) during sequential lamivudine (LAM) and adefovir dipivoxil (ADV) treatment is increasing. We investigated the antiviral efficacies of various rescue regimens in patients who failed sequential LAM-ADV treatment. Forty-eight patients (83.3% of whom were HBeAg-positive) who failed sequential LAM-ADV treatment were treated with one of the following regimens: entecavir (ETV) (1 mg) monotherapy (n=16), LAM+ADV combination therapy (n=20), or ETV (1 mg)+ADV combination therapy (n=12). All patients had confirmed genotypic resistance to both LAM and ADV and were evaluated every 12 weeks. The baseline characteristics and treatment duration did not differ significantly among the study groups. During the treatment period (median duration: 100 weeks), the decline of serum HBV DNA from baseline tended to be greatest in the ETV+ADV group at all-time points (week 48: -2.55 log(10) IU/mL, week 96: -4.27 log(10) IU/mL), but the difference was not statistically significant. The ETV+ADV group also tended to have higher virologic response rates at 96 weeks compared to the ETV monotherapy or LAM+ADV groups (40.0% vs. 20.0% or 20.0%, P=0.656), and less virologic breakthrough was observed compared to the ETV monotherapy or LAM+ADV groups (8.3% vs. 37.5% or 30.0%; P=0.219), but again, the differences were not statistically significant. HBeAg loss occurred in one patient in the ETV+ADV group, in two in the ETV monotherapy group, and in none of the LAM+ADV group. The safety profiles were similar in each arm. There was a nonsignificant tendency toward better antiviral efficacy with ETV+ADV combination therapy compared to LAM+ADV combination therapy and ETV monotherapy for MDR CHB in Korea, where tenofovir is not yet available.

UR - http://www.scopus.com/inward/record.url?scp=84886891613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886891613&partnerID=8YFLogxK

U2 - 10.3350/cmh.2013.19.1.29

DO - 10.3350/cmh.2013.19.1.29

M3 - Article

VL - 19

SP - 29

EP - 35

JO - Review of Economic Dynamics

JF - Review of Economic Dynamics

SN - 1094-2025

IS - 1

ER -